Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
MET-Amplified Lung Cancer: A New Target for XALKORI?
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
FGFR and Its Role in Treating Squamous Cell Lung Cancer
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
The Promise of Immunotherapy in Lung Cancer
Does Gilotrif Help EGFR Positive Lung Cancer Patients?
Is Progression-Free Survival Meaningful?
DDR2 Mutations in Squamous Cell Lung Cancer
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
How Do We Make EGFR Inhibitors Work Better for Patients
TH 302: New Drug May Make Tumors Less Resistant to Treatment
Should We Do Broad Sequencing of All Lung Tumors?
Create your
podcast in
minutes
It is Free
GRACEcast Pancreatic Cancer Audio
GRACEcast Radiation Oncology Audio
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Kidney Cancer Video
GRACEcast Social Work and Coping Video